Generic partners India pharma

By Dylan Bushell-Embling
Wednesday, 27 August, 2008

Biotech Capital [ASX: BTC] investee Generic Health has secured a strategic partnership with one of India's five largest pharmaceutical companies.

Under the arrangement the Indian pharmaceutical company Lupin will become a significant shareholder in Generic Health, obtaining board representation in exchange for a large cash investment.

Lupin will also provide Generic Health with access to 16 dossiers of generic drugs, including 14 already approved by the necessary regulatory bodies, as an in-kind value offer.

Generic Health announced a partnership with Actavis in June this year, and acquired Bellwether Pharma in 2007.

Content from other channels on our network

SEKO IoT solutions revolutionise on-premise laundry dosing

Six key pillars of frailty prevention and management

Protecting the people who protect us: PPE continuity during demand surge

WA steps in to ensure 'continuity' of operations at Mount Private Hospital

What healthcare boards need from risk leaders

Demystifying zero trust in OT

LION to close James Boag's Brewery in Launceston

State and federal governments extend lifeline to Nyrstar

Decarbonising compressed air: the 30% rule and the controls that fix it

CeMAT Australia 2026 to put food and beverage supply chains in focus

Driving food safety through digital traceability and transparency

New analytical method for testing gluten-free beer assessed

What's happening during CeMAT Australia 2026?

Pet food manufacturer rewires its legacy electrical cabinet

Mars expands local pet food production with new $112.6m facility now open

Generic partners India pharma

AusBiotech partners with Tenmile

Australian CDC issues update in wake of Ebola outbreak

Australia announces $7.2m diphtheria outbreak response package

Content from other channels on our network